H.Res.93 — Providing for consideration of the bill (H.R. 27) to amend the Controlled Substances Act with respect to the scheduling of fentanyl-related substances, and for other purposes.
House Roll Call
H.Res.93
| Bill | H.Res.93 — Providing for consideration of the bill (H.R. 27) to amend the Controlled Substances Act with respect to the scheduling of fentanyl-related substances, and for other purposes. |
|---|---|
| Vote question | On Agreeing to the Resolution |
| Vote type | Recorded Vote |
| Result | Passed |
| Totals | Yea 215 / Nay 208 / Present 0 / Not Voting 10 |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| R | 215 | 0 | 0 | 3 |
| D | 0 | 208 | 0 | 7 |
| I | 0 | 0 | 0 | 0 |
Research Brief
On Agreeing to the Resolution
Bill Analysis
HRES 93, introduced in the 119th Congress, provides a structured framework for the consideration of H.R. 27, which seeks to amend the Controlled Substances Act (CSA) regarding the scheduling of fentanyl-related substances. This resolution outlines the rules for debate and voting on H.R. 27, facilitating a streamlined legislative process.
The primary objective of H.R. 27 is to address the growing public health crisis associated with fentanyl and its analogs, which are synthetic opioids linked to a significant increase in overdose deaths. The bill proposes to classify fentanyl-related substances as Schedule I drugs under the CSA, thereby imposing stricter regulations on their manufacture, distribution, and possession. This classification aims to enhance law enforcement capabilities in combating the trafficking of these dangerous substances.
Funding and authorities related to this bill primarily involve the Drug Enforcement Administration (DEA), which will be tasked with enforcing the new scheduling provisions. The bill also implicates public health agencies, such as the Substance Abuse and Mental Health Services Administration (SAMHSA), which may see increased demand for resources to address substance use disorders exacerbated by fentanyl.
Key beneficiaries of H.R. 27 include law enforcement agencies, public health officials, and communities affected by the opioid epidemic, as the legislation aims to reduce the availability of fentanyl-related substances. Conversely, the bill may impose additional regulatory burdens on pharmaceutical companies and researchers working with substances that could be classified under the new scheduling.
The latest action on HRES 93 occurred when a motion to reconsider was laid on the table and agreed to without objection, indicating bipartisan support for advancing the consideration of H.R. 27. The timeline for further debate and potential voting on H.R. 27 remains to be determined, contingent on the legislative schedule.
Yea (215)
K
Ken Calvert
S
Scott Franklin
M
Mark Green
L
Lisa McClain
J
John Rutherford
D
David Schweikert
P
Pete Sessions
Nay (208)
G
Gerald Connolly
J
Jason Crow
L
Lloyd Doggett
J
John Garamendi
J
John Mannion
L
Lucy McBath
E
Eric Swalwell
R
Rashida Tlaib
S
Sylvester Turner
N
Nydia Velázquez
D
Debbie Wasserman Schultz
